Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
national blog main
10
×
boston blog main
life sciences
biotech
boston top stories
san francisco blog main
san francisco top stories
indiana blog main
indiana top stories
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
sanofi
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
eli lilly
fda
bristol-myers squibb
deals
ipo
pfizer
amgen
clinical trials
drug prices
medicare
merck
What
pharmaceutical
10
×
bio
roundup
cancer
companies
drug
new
american
based
best
continue
crash
debate
drugs
eli
giant
hasn’t
healthcare
industry
kind
latest
medicines
nash
people
policy
politicians
pressure
prices
scalps
second
trump’s
typically
u.s
acute
addresses
alzheimer’s
appetite
approval
approved
away
Language
unset
Current search:
pharmaceutical
×
" national blog main "
×
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines